PUT - SPRINTER OPEN END - BRISTOL-MYERS SQUIBB | Market Closed - Bid/Ask 12:11:04 16/05/2024 am IST | After market 12:48:17 am | |||
| 4.2 EUR | 0.00% |
|
4.205 | +0.12% |
| Current month | -2.78% | ||
| 1 month | +7.14% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 16/24/16 | 4.2 | 0.00% |
| 14/24/14 | 4.2 | 0.00% |
| 13/24/13 | 4.2 | -0.24% |
| 10/24/10 | 4.21 | -0.47% |
| 09/24/09 | 4.23 | -2.31% |
Delayed Quote Börse Stuttgart
Last update May 16, 2024 at 12:11 am IST
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Vontobel
|
| WKN | VV39WT |
| ISIN | DE000VV39WT9 |
| Date issued | 28/06/2022 |
| Strike | 90.26 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.29 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.35 € |
|---|---|
| Lowest since issue | 1.01 € |
| Spread | 0.01 € |
| Spread % | 0.24% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
25
Last Close Price
44.71
USD
Average target price
53.19
USD
Spread / Average Target
+18.98%
- Stock Market
- Certificates
- Certificat